Abstract DNA fragmentation factor is a heterodimer complex of the nuclease CAD and its specific inhibitor ICAD, which can be activated during apoptosis to induce DNA fragmentation. Although ICAD expression levels have been quantified in a variety of human cancer cells, the mechanism of ICAD gene regulation remains unknown. In this study, we identified a 106-bp TATA-less region upstream of the transcription start site as a basal promoter of the human ICAD gene. An E-Box motif, which binds transcription factors of the basic helix-loop-helix/leucine zipper family, is responsible for transcriptional activity, as demonstrated using mutated promoter-reporters. A chromatin immunoprecipitation assay further demonstrated that Myc binds to an endogenous ICAD promoter. The functional importance of Myc in the regulation of ICAD transcription was also demonstrated by knock-down of c-Myc and N-Myc gene expression, as well as their ectopic expression. Structural analysis of the human ICAD promoter and identification of factors which regulate its activity might further our understanding of the biological role of ICAD with respect to regulation of apoptosis and cancer development.
Introduction
Apoptosis or programmed cell death ensures the elimination of unwanted cells during normal development and homeostasis [1] . This process is progressively inactivated during malignant development and loss of the capacity for apoptosis is a hallmark of malignant cells. Chromatin condensation and internucleasomal DNA fragmentation are typical nuclear features and well-recognized events in apoptosis. DNA fragmentation factor (DFF) is a heterodimer protein composed of a 40-kDa caspase-activated DNase (CAD) otherwise known as DFF40, and its cognate 45-kDa inhibitor (inhibitor of CAD: ICAD or DFF45 [2] [3] [4] [5] [6] [7] [8] ). Both human genes map to 1p36 [9, 10] . CAD is thought to be responsible for the majority of nuclear activity resulting in chromosomal DNA fragmentation. When apoptosis is activated, ICAD is cleaved by executor caspases, mainly caspase-3, into three fragments, after which it dissociates from CAD, resulting in CAD activation.
Thus, the DFF complex may play a role in malignant transformation, and up-or down-regulation of ICAD/CAD expression might correlate with cancer aggression. Expression levels of ICAD have been examined in a variety of human cancers. For example, ICAD expression is downregulated during the exponential growth phase of human colon carcinoma cells [11] . In some neuroblastomas, preferential ICAD expression is observed in low-stage, but not in their high grade [12] . Other research suggests that downregulation of ICAD may contribute to tumor growth and lymph node metastasis in esophageal carcinoma [13] , and that ICAD expression might serve as a marker of aggressive tumor behavior with an associated poor prognosis in ovarian cancer [14] . We have previously demonstrated that the hepatitis C virus core protein, which not only encodes the viral nucleocapsid but has a number of properties enabling persistent viral infection, induces gene expression of ICAD, thereby increasing steady-state levels of the ICAD protein [15] . To date, the mechanism of transcriptional regulation of the ICAD gene is not well understood. Analysis of the gene structure of mouse ICAD showed that a 118-bp flanking region of the ICAD gene is required for promoter activity [16] . In this study, we identified a functional promoter of the human ICAD gene and investigated the role of c-Myc and N-Myc in regulation of the ICAD promoter.
Materials and methods

Cell cultures
Human hepatoblastoma cells (Huh-7), human oral squamous carcinoma cells (HSC-2, HSC-3 and Ca22-9), mouse neuroblastoma cells (IMR-32 and GOTO) and mouse 3T3 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 units/ml of penicillin, and 100 mg/ml of streptomycin and kept at 37°C in a 5% CO 2 incubator.
Cloning of the 5 0 -upstream region of the human ICAD gene Human genomic DNA was isolated from Huh-7 cell lines using the QIAamp DNA Mini kit according to the manufacturer's instructions (QIAGEN). A 5 0 -upstream region of the ICAD gene was amplified by PCR using primers based on the genomic DNA sequence of the human ICAD gene (GenBank accession No. NM_004401). Primers containing EcoRI sites were used as follows: forward (5 0 -GA-ATTCAGGCTGGTCTCAAACTACTG-3 0 ) and reverse (5 0 -GAATTCGATCTCGCCAGATTCTGGTA-3 0 ). The PCR reaction was carried out at 94°C for 1 min, 55°C for 1.5 min, and 72°C for 2 min, for total of 35 cycles. Each PCR product was purified and subcloned into a pGEM-T Easy vector (Promega), followed by sequencing using an ABI PRISM 310 automated DNA sequencer (Applied Biosystems).
5
0 rapid amplification of cDNA ends (5 0 -RACE) assay
The 5 0 ends of the ICAD transcript were cloned by 5 0 -RACE using a Gene Racer RACE-Ready cDNA kit in accordance with the manufacturer's instructions (Invitrogen). Double-stranded cDNA molecules prepared from human liver poly(A) + RNAs ligated by exposure to the adaptor were amplified in a primary PCR reaction using the adaptor primer 1 and the ICAD gene-specific antisense primer ICA1AS (5 0 -GTGCTGTTCGCGGCTGTAGTT-3 0 , nt -147 to -173), followed by a secondary PCR reaction using nested oligonucleotides, the adaptor primer 2, and the antisense ICAD specific primer ICA2AS (5 0 -CACGG  TGACTGGTGTCAGGGACTTATC-3 0 , nt -228 to -254). PCR products were purified and cloned, followed by nucleotide sequencing as described above.
Plasmid constructions
The 1-kb sequence containing the human ICAD promoter was excised by digestion of the above-mentioned pGEM-T vector with SacI and HindIII, and then cloned into the firefly-luciferase-expressing reporter plasmid pGL3-Basic (Promega), resulting in pLUC1005. A series of constructs with 5 0 end-deletions of the ICAD promoter were created by PCR amplification using the reverse primer (5 0 -CAA GCTTGCCTCCACAAGGTGGGACCTG-3 0 ) and the following forward primers:
0 (nt -90 to +71), and 5 0 -GGCTAG CCCAGATGGTAAATATACACAA-3 0 (nt -43 to +71). Each SacI/HindIII fragment was inserted into the pGL3-basic vector to yield pLUC(-936/+71), pLUC(-622/+71), pLUC(-272/+71), pLUC(-205/+71), pLUC(-145/+71), pLUC(-106/+71), pLUC(-90/+71) and pLUC(-43/+71).
Transfection and reporter assay
Huh-7 cells were seeded at 5 9 10 4 cells/well in 24-well plates and maintained at 37°C in a 5% CO 2 /95% atmosphere. DNA transfection of cells with each ICADpromoter-luciferase construct (1 lg) with an internal control vector pRL-TK (0.1 lg) (Promega) was performed with Trans IT LT-1 (Mirus) during 6-h of incubation. Cells were then rinsed with phosphate-buffered saline (PBS) 48 h after transfection, and luciferase activity was measured in the cell lysate using dual luciferase assay reagents (Promega) [17] . Firefly luciferase activity was standardized according to Renilla luciferase activity.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed using the ChIP assay kit (Upstate). Briefly, cells in 100-mm dishes were grown to 70% confluency over 48 h. The chromatin from formaldehyde-fixed cells was sonicated and immunoprecipitated using mouse monoclonal anti-c-Myc or anti-N-Myc antibodies (Santa Cruz). 
Western blotting
Cells were washed with PBS and lysed in SDS sample buffer. Cell lysate samples were separated by 10% SDS-polyacrylamide gel electrophoresis and electrotransferred to a polyvinylidene difluoride membrane (Immobilion; Millipore). After blocking in nonfat milk solution (Blocking One; Nakaraitesk), the membranes were probed with monoclonal antibody against the ICAD protein (Santa Cruz), c-Myc (Sigma), or N-Myc (Santa Cruz), as the primary antibody for 1 h. After being washed, the membranes were incubated with horseradish peroxidase-conjugated antimouse immunoglobulin as the secondary antibody, followed by visualization with SuperSignal West Pico Chemiluminescent Substrate (Pierce Biotechnology). 0 , and 5 0 -TATTCGCGCGTATAGCGGT-3 0 for the negative control. Huh-7 cells were transfected with 100 pmol/ml siRNA using FuGENE6 (Roche) in Opti-MEM I (Invitrogen), after which the medium was replaced by standard DMEM after 6 h of transfection.
RNA preparation and real-time quantitative RT-PCR
Total RNA was extracted using Trizol reagent (Invitrogen) according to the manufacturer's protocol. First-strand cDNAs were synthesized using the SuperScriptIII FirstStrand Synthesis kit (Invitrogen) and then used as templates for real-time PCR. Quantitative PCR was performed using the ABI Prism 7700 sequence detection system using Taq-Man Gene Expression assays (Applied Biosystems). The standard curve was created using serially diluted total RNA obtained from Huh-7 cultures and b-actin was chosen as the internal standard to control for variability in amplification. Amplification was performed at 95°C for 10 min, followed by 40 cycles of amplification at 95°C for 15 s and 60°C for 60 s.
Results and discussion
Localization of transcription start sites of the human ICAD gene Precise localization of transcription start sites of the ICAD gene was examined in human hepatoma Huh-7 cells by 5 0 -RACE analysis. A fragment of approximately 100 bp was obtained (Fig. 1a) and cloned, after which sequencing analysis of several cDNA clones identified two of 5 0 termini (Fig. 1b ). These were located 71 and 68 nucleotides upstream from the translation start codon of the ICAD gene. From a database search of the DBTSS [18] , we found that these are two of multiple sites for putative transcription initiation for the human ICAD gene. Although transcription may be initiated at both sites, the upper site was designated position +1 in this study.
Characterization of the ICAD gene promoter
To examine potential regulatory sequences involved in ICAD gene expression, a 1 kb 5 0 -upstream region of the ICAD gene was sequenced and analyzed. The overall GC content of the 1-kb genomic DNA fragment was 46%, while GC content among the 200 bp proximal to the ATG start codon was approximately 62%. A search of transcription consensus motifs using the TRANSFAC database [19] demonstrated that none of the major eukaryotic promoter elements, TATA-, CCAAT-, or GC box, were located within 200 bp upstream of the transcription start site, although a TATA-like element was found more than 400 bp upstream from the start sites, indicating that the human ICAD gene has a TATA-less promoter. No CpG island, which is frequently observed in the TATA-less promoter, was found by screening with the CpG island searcher (http://cpgislands.usc.edu/). Absence of a TATAlike sequence upstream of the transcription start site has also been reported for the mouse ICAD gene, suggesting that TATA-less promoters might be a common feature in transcriptional regulation of the ICAD gene.
As shown in Fig. 1b , the 1-kb sequence contains potential binding sites for several transcription factors. The ability of the 5 0 -upstream region of the ICAD gene to function as a promoter was assessed by its capacity to drive the expression of a luciferase reporter gene. A series of constructs in which genomic DNA fragments were fused to a promoterless firefly luciferase gene of the pGL3-basic vector were generated with the 3 0 end always terminating +71 bp from the (Fig. 2) . Promoter activity was assessed by measuring luciferase activity in transiently transfected Huh-7 cells. Luciferase activity was normalized to Renilla luciferase activity. As shown in Fig. 2 on the right, the region extending from -936 to +71 had promoter activity since luciferase activity of the reporter gene was 45-fold that of the empty vector. A 5 0 deletion of the promoter sequence to -662(pLuc(-662/ +71)) enhanced promoter activity, and successive removal of nucleotides from -272 to -106 also enhanced promoter activity, suggesting the possibility of negative regulatory elements within the -936/-622 and -272/-106 regions.
When the sequence from -106 to -90 was removed (pLuc(-90/+71)), promoter activity fell to parallel that of the pGL3 basic vector. This suggests the presence of a critical element in the region extending from -106 to -90, thus, we have identified the region 106 bp upstream of the transcription start site as the basal promoter of the human ICAD gene.
Myc and USF enhance ICAD promoter activity As indicated in Fig. 1b factors (USF). Within this region, there is a canonical E-box sequence (5 0 -CACGTG-3 0 ) located between -103 and -98. E box motifs are known to bind to transcription factors of the basic helix-loop-helix/leucine zipper (bHLH LZ) family, including Myc and USF [20] [21] [22] [23] . We examined the potential role of E-box-binding proteins, Myc and USF, in potentiating ICAD gene transcription. Myc is bound to a partner protein Max via a bHLH LZ domain and the Myc-Max heterodimer activates transcription by binding to an E-box sequence [24, 25] . Max is present in greater amounts than Myc since the Myc transcript and protein have shorter half-lives compared to Max [26, 27] . Therefore, it is highly likely that Myc is the limiting, regulated component of the heterodimer. To examine the potential role of E box binding proteins, Huh-7 cells were co-transfected with luciferase reporter plasmids and expression vectors for c-Myc, N-Myc, USF1, and USF2 (Fig. 3a) . Luciferase activity of the -145/+71 promoter construct increased 2-to 5-fold, and 1.5-to 2-fold, when co-expressed with Myc or USF, respectively. The effect of c-Myc and N-Myc on activity of the -90/+71 construct was less than for the -145/+71 construct. USF expression did not enhance activity of the -90/+71 construct.
To further investigate involvement of the E box sequence in ICAD promoter activity, a reporter construct with an E box mutation (CCCGCG) was constructed and luciferase activity was examined in transfected cells (Fig. 3b) . The E box mutation resulted in marked downregulation of reporter gene expression and the reporter activity expressed from the E-box mutant was little increased when co-expressed with Myc, suggesting a functionally important role of the -106/-90 region E box motif with regard to basal transcriptional activation of the ICAD promoter. These data indicates that E-box-binding proteins, especially Myc, actively participate in positive regulation of the human ICAD promoter. (Fig. 4a) [16] . Proteins were cross-linked to genomic DNA isolated not only from human (Huh-7) but mouse (IMR-32 and GOTO) cells, followed by immunoprecipitation with normal rabbit IgG or polyclonal antibodies to either c-Myc or N-Myc. IMR-32 and GOTO are neuroblastoma cells with N-Myc gene amplification [28] obtained from IMR-32 and GOTO cells, which were immunoprecipitated with anti-N-Myc antibody. These results demonstrate that Myc forms a complex with the human ICAD promoter in cells, presumably through binding to the E-box sequence.
Myc-dependent expression of the ICAD protein
The above data suggests that the ICAD promoter is regulated by endogenous Myc proteins. This assumption is supported by the loss-of-function studies shown in Fig. 5a . We employed siRNA (small interference RNA) transfection to knock-down the expression of c-Myc or N-Myc in cells, after which we analyzed the effect of reduced Myc expression on steady state levels of the ICAD protein by Western blotting. Treatment with siRNA specific for either c-Myc or N-Myc markedly reduced ICAD expression without affecting the expression of b-actin. In contrast, control siRNA did not reduce ICAD levels. We further investigated the effect of over-expression of Myc on ICAD protein levels (Fig. 5b) . Transfection of Huh-7 and mouse 3T3 cells with a c-Myc or N-Myc expression vector enhanced ICAD protein levels with an effect that was less pronounced than in the Several studies have shown up-or down-regulation of ICAD in a variety of human cancers [11-14, 29, 30] . Although transcriptional deregulation is presumably involved in this aberrant expression of ICAD, little is known about the transcriptional regulation of ICAD in human cells. This work was done to characterize the human ICAD promoter and to examine transcription factors which may be involved in its regulation. We experimentally determined putative transcription start sites by employing the 5 0 -RACE method, and identified a promoter region required for basal ICAD gene expression using promoterreporter constructs with progressive deletions. A combined study of site-directed mutagenesis of a reporter construct and chromatin immunoprecipitation revealed the importance of an E box Myc-binding motif located at position -103 to -98 from the transcription start sites, as well as an in vivo interaction between c-Myc and N-Myc and the proximal ICAD promoter. Furthermore, we demonstrated the functional importance of Myc proteins with regard to transcriptional regulation of the ICAD gene from studies examining ectopic expression of c-Myc and N-Myc, as well as with RNAi technology. We showed that expression levels of ICAD and Myc correlate in some tumors.
c-Myc and N-Myc are transcription factors of the bHLH LZ family that bind to the E box sequence within promoters to control proliferation, cell differentiation, and apoptosis [25, 31, 32] . c-myc and N-myc genes are deregulated in a number of human cancers and influence proliferation and growth. A link between Myc and cancer is well established both in vivo and in vitro, and oncogenic activation of Myc has been observed to promote the development of a number of clinically significant cancers [25, 33] . However, the molecular and cellular mechanisms of Myc-mediated transformation are not fully understood. Although a variety of Myc target genes were identified and recruitment of Myc to the target promoters such as prothymosin and telomerase were shown [34] , there has been no direct evidence on involvement of Myc in regulation of ICAD expression. It is known that c-Myc activation usually occurs during the later stages of carcinoma in humans. Conversely, in premalignant cells, c-Myc is a robust stimulator of apoptosis and programmed cell death [32] . One area of investigation into cancer cell death mechanisms centers on the mechanism by which c-Myc stimulates or suppresses apoptosis. For instance, Myc has been reported to potentiate apoptosis through both p53-dependent and -independent mechanisms [35, 36] . Myc controls the balance between proand anti-apoptotic factors at the level of the mitochondria, thereby regulating cytochrome C release and activation of downstream caspases [37, 38] . Involvement of Myc in up-regulation of ICAD expression as demonstrated in this study might present a novel mechanism of Myc-dependent inhibition of apoptosis. It is possible that elevated levels of ICAD in cells inhibit activation of endonuclear activity, thereby increasing the threshold for apoptosis signaling.
Kawane et al. have reported on the structure and analyzed the promoter of a murine ICAD gene, by which they demonstrated that a 118-bp flanking region of the ICAD gene is required for its transcription [16] . The mouse sequence shares approximately 82% homology with a corresponding upstream region of the human ICAD gene. The mouse ICAD promoter has a number of potential binding sites for transcription factors, such as Ikaros, c-Rel, Myc, and Gfi-1 [16] . Conservation of the Myc-binding motif among human and murine promoters suggests a functional significance of Myc in transcriptional regulation of ICAD expression.
In conclusion, this is the first report to identify a functional promoter of the human ICAD gene, and to demonstrate that Myc proteins are able to positively regulate ICAD gene expression. Extensive apoptosis research to date has shown that tumor aggression depends on various defects in apoptosis signaling [39] . Further investigation into the molecular events linking Myc expression with ICAD gene regulation may provide insight into Myc's role in cell proliferation, transformation and apoptosis.
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